2610024E20Rik Activators
2610024E20Rik activators encompass a spectrum of chemical compounds that intervene in cellular signaling pathways, culminating in the enhancement of 2610024E20Rik function. Compounds such as Forskolin and Genistein calibrate intracellular signaling by elevating cAMP levels and inhibiting tyrosine kinases, respectively. Forskolin's activation of PKA possibly phosphorylates proteins that modulate 2610024E20Rik activity, while Genistein's kinase inhibition might reduce competitive regulatory influences on 2610024E20Rik. The lipid signaling effector Sphingosine-1-phosphate and the calcium disruptor Thapsigargin, each initiate cascades that indirectly enhance 2610024E20Rik via lipid and calcium-mediated signaling pathways. Chemicals falling under the category of 2610024E20Rik Activators are distinguished by their function to increase the activity of the 2610024E20Rik gene. The process to pinpoint these activators typically starts with the utilization of high-throughput screening (HTS) techniques, which allow for the systematic testing of extensive libraries of diverse compounds.
This method involves the application of a reporter assay that is specifically designed to detect the activation of the 2610024E20Rik gene. Within this assay framework, a reporter gene – which is engineered to produce a measurable output, such as fluorescence or luminescence when expressed – is placed under the regulatory control of the 2610024E20Rik gene's promoter. As a result, when a compound interacts with and activates this promoter, the reporter gene's expression is induced, leading to an observable signal. The magnitude of this signal directly reflects the compound's efficacy in activating the gene. Only those compounds that result in a pronounced increase in the reporter activity are selected for subsequent scrutiny. This step is critical in the filtration process, zeroing in on compounds that can trigger a rise in gene activity from among the multitude of chemical variants tested.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that raises intracellular calcium levels. Increased calcium can activate calcium-dependent protein kinases that might enhance the activity of 2610024E20Rik through calcium signaling pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is an activator of Protein Kinase C (PKC). PKC activation could lead to phosphorylation of downstream targets, potentially increasing the activity of 2610024E20Rik through PKC-mediated signaling pathways. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate is a lipid signaling molecule that activates sphingosine-1-phosphate receptors leading to various downstream signaling cascades that could enhance the functional activity of 2610024E20Rik. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, leading to increases in cAMP and/or cGMP levels within the cell. This elevation could enhance 2610024E20Rik activity indirectly through cAMP/cGMP-dependent signaling pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is known to inhibit certain protein kinases. Inhibition of competitive signaling pathways may indirectly increase the activity of 2610024E20Rik by reducing phosphorylation on inhibitory sites or by shifting the balance to favor its pathway. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor, which leads to increased cytosolic calcium levels. The rise in calcium could enhance the activity of 2610024E20Rik by activating calcium-dependent pathways and proteins. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, potentially increasing the activity of 2610024E20Rik by altering downstream signaling of the PI3K/AKT pathway, which could affect processes where 2610024E20Rik is involved. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is another MEK inhibitor, which could allow for the upregulation of 2610024E20Rik activity by inhibiting the MAPK/ERK pathway and thus potentially modulating signaling pathways in which 2610024E20Rik is involved. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is a calcium ionophore, similar to Ionomycin, and it also increases intracellular calcium, which could enhance the activity of 2610024E20Rik through calcium-dependent signaling pathways. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor; however, by selectively inhibiting certain kinases, it could lead to the activation of 2610024E20Rik by lifting the inhibition on pathways or processes where 2610024E20Rik is involved. | ||||||